Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events

Jennifer J. Kwak, Sree Harsha Tirumani, Annick D. Van den Abbeele, Phillip J. Koo, Heather A. Jacene

Research output: Contribution to journalArticle

Abstract

Cancer immunotherapy is changing the imaging evaluation of cancer treatment response and treatment-related toxic effects. New emerging patterns of treatment response and treatment-related toxic effects after treatment with immunomodulating agents have been observed. Treatment response after immunomodulatory therapy can be associated with significantly delayed decrease in tumor size, and new or enlarging tumors observed soon after completion of treatment may not reflect disease progression. In addition, activation of the immune system to fight cancer may lead to unwanted autoimmune-mediated toxic effects that could be mistaken for metastatic disease or misdiagnosed as a non–treatment-related process and delay appropriate clinical management. Radiologists must recognize the novel treatment response patterns and the wide range of autoimmune toxic effects, which should not be mistaken for treatment failure or metastatic disease progression.

Original languageEnglish (US)
Pages (from-to)424-437
Number of pages14
JournalRadiographics
Volume35
Issue number2
DOIs
StatePublished - Jan 1 2015

    Fingerprint

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Kwak, J. J., Tirumani, S. H., Van den Abbeele, A. D., Koo, P. J., & Jacene, H. A. (2015). Cancer immunotherapy: Imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics, 35(2), 424-437. https://doi.org/10.1148/rg.352140121